PolyPid (PYPD) Stock Price, News & Analysis

Company Overview

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing locally administered therapies designed to provide controlled and sustained drug delivery at treatment sites. The company’s proprietary PLEX polymer-lipid encapsulation matrix is intended to release therapeutic agents over an extended period, with the goal of improving treatment effectiveness and reducing the need for repeated systemic dosing.

PolyPid’s lead product candidate is D-PLEX100, an investigational formulation containing doxycycline that is designed for administration at surgical sites. The product has been developed primarily for the prevention of surgical-site infections, including infections associated with colorectal and other abdominal procedures. D-PLEX100 has been evaluated in clinical studies, including late-stage trials, although its development and regulatory status may change as the company assesses clinical and business priorities.

Founded in 2005 and headquartered in Israel, PolyPid has focused its research and development activities on applying its drug-delivery platform to surgical care and other localized treatment settings. The company has conducted clinical development and business activities involving international markets, including the United States, where its securities have traded under the symbol PYPD. PolyPid’s pipeline and corporate activities have centered on advancing its proprietary delivery technology and evaluating potential partnerships or applications for its products.

Key Stats

• Today's Range: $5.06 to $5.55
• 50-Day Range: $3.75 to $5.45
• 52-Week Range: $3.06 to $5.73
• Volume: 167,717 shs
• Average Volume: 81,616 shs
• Market Capitalization: $99.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.33
• Consensus Rating: Moderate Buy

PolyPid Stock Analysis - MarketRank™

PolyPid scored higher than 58% of companies evaluated by MarketBeat, and ranked 361st out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PolyPid has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PolyPid has a consensus price target of $11.33, representing about 118.4% upside from its current price of $5.19.

Amount of Analyst Coverage

PolyPid has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PolyPid are expected to decrease in the coming year, from ($0.92) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PolyPid is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PolyPid is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PolyPid has a P/B Ratio of 7.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.91% of the float of PolyPid has been sold short.

Short Interest Ratio / Days to Cover

PolyPid has a short interest ratio ("days to cover") of 1.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PolyPid has recently decreased by 33.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PolyPid does not currently pay a dividend.

Dividend Growth

PolyPid does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.33

News Sentiment

PolyPid has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for PolyPid this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PolyPid insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

26.47% of the stock of PolyPid is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PYPD
• CIK: 1611842
• Web: www.polypid.com
• Phone: 972-74-719-5700
• Fax: N/A
• Employees: 75
• Year Founded: 2008

Price Target and Rating

• Average Price Target for PolyPid: $11.33
• High Price Target: $13.00
• Low Price Target: $9.00
• Potential Upside/Downside: +118.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -311.08%
• Return on Assets: -150.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.35
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 7.52

Miscellaneous

• Outstanding Shares: 19,080,000
• Free Float: 14,369,000
• Market Cap: $99.03 million
• Optionable: No Data
• Beta: 1.38